Study of IRX4204 for Treatment of Early Parkinson's Disease
NCT02438215
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease
Interventions
DRUG:
IRX4204
Sponsor
Io Therapeutics